Vinca (Dienogest 2mg)

Vinca (Dienogest 2mg)

Indication: Endometriosis

Dosage: 1 tab daily without any break.  May start on any day of menstrual cycle

Administration: May be taken with or without food: Preferably taken at the same time each day
Place of Origin: Spain

Contraindication: Hypersensitivity. Active venous thromboembolic disorder; DM w/ vascular involvement; known or suspected sex hormone-dependent malignancies; undiagnosed vag bleeding. Presence or history of arterial & CV disease (eg, MI, CVA, ischemic heart disease); severe hepatic disease as long as liver function values have not returned to normal; liver tumours (benign or malignant).

Special Precaution: May slightly increased risk of stroke in women w/ HTN; venous thromboembolism (DVT, pulmonary embolism); breast cancer. Discontinue use in case of long-term immobilization & not to resume treatment until 2 wk after complete remobilization (at least 4 wk in advance in the case of elective surgery); recurrence of cholestatic jaundice &/or pruritus which occurred 1st during pregnancy or previous use of sex steroids. Increased risk of thromboembolism in the puerperium. Stop treatment at once if there are symptoms of arterial or venous thrombotic event or suspicion thereof. Consider hepatic tumour in the differential diagnosis when severe abdominal pain, liver enlargement or signs of intra-abdominal hemorrhage occur. Changes in bleeding pattern. Presence of significant risk factors for osteoporosis; should have adequate intake of Ca & vit D. History of depression; discontinue if depression recurs to a serious degree. Diabetic women, especially those w/ history of gestational DM. History of chloasma gravidarum; avoid exposure to the sun or UV radiation during therapy. Women w/ history of extrauterine pregnancy or tube function impairment. Persistent ovarian follicles may occur. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Non-hormonal (eg, barrier method) methods should be used if contraception is required. Should not be administered during pregnancy. Not recommended during lactation. Not indicated in childn prior to menarche. Adolescents 12-18 yr (mean decrease in bone mineral density over a treatment period of 12 mth).